Eagle Meds Services
Tafinlar (dabrafenib)
Available to sourceHuman Prescription DrugOncology & Specialty

Tafinlar (dabrafenib)

Active ingredients · Dabrafenib Mesylate

10 mg/1 · Tablet For Suspension
By Novartis Pharmaceuticals Corporation
NDC
0078-1154
Route
Oral
Therapeutic class
Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Kinase Inhibitor , Organic Anion Transporter 1 Inhibitors [MoA], Organic Anion Transporter 3 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], Protein Kinase Inhibitors [MoA]
Marketing category
NDA

Package sizes

  • 210 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-1154-21)NDC 0078-1154-21Available to order

Additional information

Full prescribing information for this product is available on request. Submit a sourcing request and our team will share lot details, dating, and current pricing.

Request this medication

Send a request and we'll respond with availability, lot details, and pricing within 2 business hours.

Requesting
Tafinlar (dabrafenib)
NDC 0078-1154